Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06586957 · ClinicalTrials.gov registry record · Phase 1

A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors

A Phase 1 study of Ovarian Cancer and Solid Tumor, sponsored by NiKang Therapeutics.

Recruiting
Registry status
Phase 1
Development phase
150
Enrollment target
19
Study locations

NCT06586957 is a Phase 1 study of Ovarian Cancer and Solid Tumor that is actively recruiting participants, run by NiKang Therapeutics. The registered enrollment target is 150 participants, below the 728-participant average among 322 other Ovarian Cancer trials with a reported enrollment target (79% lower). The trial reports 19 study locations across 13 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06586957, a Phase 1 study of Ovarian Cancer and Solid Tumor, is actively recruiting participants, sponsored by NiKang Therapeutics.

RECRUITING
Registry status
Phase 1
Development phase
150 participants
Enrollment target
19
Study locations

Study Summary

The goal of the Dose Escalation phase of the study is to evaluate the safety, tolerability, pharmacokinetics (PK) and preliminary anti-tumor activity to determine the preliminary recommended dose for expansion (RDE) of NKT3964 in adults with advanced or metastatic solid tumors. The goal of the Expansion phase of the study is to evaluate the preliminary anti-tumor activity of NKT3964 at the RDE based on objective response rate (ORR) and determine the preliminary recommended Phase 2 dose (RP2D).

Conditions Studied

Ovarian Cancer Solid Tumor Advanced Solid Tumor Solid Tumor, Adult Ovarian Neoplasms Ovarian Carcinoma Endometrial Neoplasms Metastatic Ovarian Carcinoma Metastatic Tumor Endometrial Diseases

Interventions

  • DRUG NKT3964

Study Locations (19)

California

  • University of California - Los Angeles - Los Angeles
  • UCSF - San Francisco

Florida

  • Florida Cancer Specialists & Research Institute - Lake Mary
  • AdventHealth Cancer Institute - Orlando

Georgia

  • Emory Winship Cancer Institute - Atlanta
  • Augusta University - Augusta

Pennsylvania

  • Sidney Kimmell Cancer Center - Jefferson Health - Philadelphia
  • UPMC - Pittsburgh

Texas

  • NEXT Oncology - Austin
  • UT Southwestern - Dallas

Virginia

  • University of Virginia - Charlottesville
  • NEXT Virginia - Fairfax

Arkansas

  • University of Arkansas Medical School - Little Rock

Colorado

  • SCRI at HealthOne - Denver

Trial Details

FieldValue
Enrollment Target 150 participants
Start Date 2024-09-19
Est. Completion 2029-05
Phase Phase 1

Sponsor

NiKang Therapeutics

5 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06586957

The ClinicalTrials.gov registry entry for NCT06586957 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 150 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 728-participant average among 322 other Ovarian Cancer trials with a reported enrollment target (79% lower). The listed sponsor is NiKang Therapeutics, which has 5 total studies on file at ClinicalTrials.gov.

The record links to 10 conditions, with Ovarian Cancer appearing as the primary indexed condition, and to 1 intervention - of which NKT3964 is the first listed.

NCT06586957 reports 19 study locations spanning 13 distinct geographic areas - top geographies include California, Florida, Georgia.

Frequently Asked Questions

What is clinical trial NCT06586957 about?

NCT06586957 is a clinical study titled "A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors". The goal of the Dose Escalation phase of the study is to evaluate the safety, tolerability, pharmacokinetics (PK) and preliminary anti-tumor activity to determine the preliminary recommended dose for expansion (RDE) of NKT3964 in adults with advanced or metastatic solid tumors. The goal of the Expan...

What is the current status of trial NCT06586957?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 150 participants. The study started on 2024-09-19. Estimated completion is 2029-05.

What conditions does trial NCT06586957 study?

This clinical trial studies the following conditions: Ovarian Cancer, Solid Tumor, Advanced Solid Tumor, Solid Tumor, Adult, Ovarian Neoplasms.

What interventions are being tested in trial NCT06586957?

The interventions under investigation include: NKT3964 (DRUG).

Who is sponsoring clinical trial NCT06586957?

This trial is sponsored by NiKang Therapeutics, which has 5 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06586957 being conducted?

This trial has 19 study locations across Arkansas, California, Colorado, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Ovarian Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Ovarian Cancer

All registered trials for this condition

Solid Tumor

All registered trials for this condition

Arkansas

All trials with a study site in Arkansas

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.